The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million in 2030
Advances in biotechnology have enabled the development ofversatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ(brain perfusion) blood–brain barrier models, allowing more effective and safedelivery of drugs across brain capillaries
Roots Analysis is pleased toannounce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2ndEdition), 2020-2030: Focus on Non-Invasive Drug Delivery TechnologyPlatforms and Therapeutics.”
The report features an extensive study of the currentmarket landscape, offering an informed opinion on the likely adoption of BBBpenetration technologies and affiliated drugs, over the next decade. The reportfeatures an in-depth analysis, highlighting the diverse capabilities ofstakeholders engaged in this domain. In addition to other elements, the studyincludes:
§ Anoverview of the overall landscape of BBB penetration technologies, featuring anin-depth analysis of the technologies based on a number of parameters
§ Adetailed assessment of the current market landscape of BBB penetrant drugs.
§ Identificationof contemporary market trends, depicted using three schematic representations,which include [A] a tree map representation, [B] a bubble analysis and [C] aninformative heptagon representation.
§ Aninsightful competitiveness analysis of BBB penetration technologies, takinginto consideration the supplier power and key technology specific information.
§ Elaborateprofiles of prominent technology developers that are engaged in the developmentof at least four drugs.
§ Ananalysis of the partnerships that have been established in the domain, in theperiod between 2014 and 2020.
§ Anelaborate discussion on the deal structures of various types of technologylicensing agreements inked in this domain.
§ Ananalysis of the investments made in the domain, in the period between 2014 and2020 (till March).
§ Anin-depth analysis of the various patents that have been filed / granted relatedto BBB penetration technologies, till November 2019.
§ Aninsightful chessboard analysis highlighting the most preferred / popular drugdevelopment strategies / paths adopted by majority of the drug developers (withclinical candidates) in order to progress their lead drug candidates.
§ Anassessment of the most commonly targeted disorders affecting the CNS, shortlistedon the basis of number of BBB penetrant drugs in development.
§ Alist of 240+ drug developers targeting Alzheimer’s disease and Parkinson’sdisease that are likely to partner with BBB penetration technology providers.
§ Acase study highlighting the working principle of the most common approachesthat are being employed for the development of BBB penetration technologies.
§ Aninformative analysis of contemporary Google Trends in the time period between2015 and 2019 (till December) and insights generated from recent news articlesrelated to the BBB, indicating the increasing popularity of this domain.
A detailed market forecast,featuring analysis of the current and projected future opportunity across keymarket segments (listed below) :
§ Type of Payment ModelAdopted
§ Upfront payments
§ Milestone payments
§ Type of Molecule
§ Small Molecules
§ Biologics
§ Target DiseaseIndication
§ Brain Metastases inBreast Cancer
§ GlioblastomaMultiforme
§ Hunter Syndrome
§ Hurler Syndrome
§ Leading TechnologyPlatforms
§ G®-Technology
§ J-Brain Cargo®Technology
§ LRP-1 Technology
§ Trojan HorseTechnology
§ Leading Drug Developers
§ 2-BBB
§ Angiochem
§ ArmaGen
§ JCR Pharmaceuticals
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia-Pacific
Transcripts ofinterviews held with the following senior level representatives of stakeholdercompanies
§ Ram Bhatt (ChiefExecutive Officer, Chairman and Founder, InnovativeCalifornia Biosciences International (ICBI))
§ Frank S Walsh (ChiefExecutive Officer and Founder, Ossianix)
§ Pieter Gaillard(Chief Executive Officer and Co-Founder, 2-BBB)
§ Rob Hutchison (ChiefExecutive Officer and Chairman, biOasisTechnologies)
§ Mathias Schmidt(Chief Executive Officer, ArmaGen)
§ Mark L Peterson(Chief Operating Officer, CycleniumPharma)
§ Xavier Rivero (ChiefOperating Officer, SagetisBiotech)
§ Carole Desseaux (Headof Clinical Affairs, CarThera)
§ Jamal Temsamani (Headof Drug Development, Vect-Horus)
§ Kevin Kit Parker(Professor, Wyss Institute, Harvard University)
Keycompanies covered in the report
§ Angiochem
§ ArmaGen
§ BioArctic
§ Cyclenium Pharma
§ Denali Therapeutics
§ ICB International
§ Iproteos
§ JCR Pharmaceuticals
§ Lauren Sciences
§ Medesis Pharma
§ Ossianix
§ Vect-Horus
Foradditional details, please visit
https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html oremail sales@rootsanalysis.com
Youmay also be interested in the following titles:
1. Novel Coronavirus(Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
2. DNA-Encoded Libraries:Platforms and Services Market
3. Global StemCells Market: Focus on Clinical Therapies, 2020–2030
Contact:
GauravChaudhary
+1(415) 800 3415
